Flag of the European Union EU Clinical Trials Register Help

Clinical trials for BASFI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: BASFI. Displaying page 3 of 3.
    « Previous 1  2  3 
    EudraCT Number: 2015-000541-24 Sponsor Protocol Number: B1801381 Start Date*: 2016-01-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Multicenter Open-Label Study of Etanercept Withdrawal and Retreatment in Subjects with Non-Radiographic Axial Spondyloarthritis who Achieved Adequate 24 Week Response
    Medical condition: Spondyloarthritis (SpA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed) PL (Completed) HU (Completed) SE (Completed) ES (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003065-95 Sponsor Protocol Number: AS0011 Start Date*: 2019-06-11
    Sponsor Name:UCB Biopharma SRL
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS
    Medical condition: Ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) BG (Completed) FR (Completed) ES (Restarted) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001102-42 Sponsor Protocol Number: AS0008 Start Date*: 2016-11-21
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPOND...
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) CZ (Completed) DE (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011591-30 Sponsor Protocol Number: CAIN457A2209E1 Start Date*: 2010-09-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with moderate to severe ankylosing spondylitis
    Medical condition: Ankylosing spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000226-58 Sponsor Protocol Number: A3921120 Start Date*: 2018-07-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS)
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) CZ (Completed) ES (Completed) AT (Prematurely Ended) GB (Completed) DE (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-000241-74 Sponsor Protocol Number: CNTO148AKS3001 Start Date*: 2014-12-30
    Sponsor Name:Janssen Biologics, BV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Ankylosing Spondylitis
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001060-35 Sponsor Protocol Number: CLR_18_07 Start Date*: 2018-08-29
    Sponsor Name:Sun Pharmaceutical Industries Limited (SPIL)
    Full Title: A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
    Medical condition: Psoriatic Arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10076297 Non-radiographic axial spondyloarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005689-39 Sponsor Protocol Number: A3921119 Start Date*: 2013-06-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York 10017
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)
    Medical condition: Ankylosing Spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) NL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-020077-16 Sponsor Protocol Number: B1801031 Start Date*: 2010-12-22
    Sponsor Name:Pfizer, S.A
    Full Title: Estudio de 12 semanas de duración, multicéntrico, doble ciego, controlado con placebo, aleatorizado de etanercept con un AINE de base en el tratamiento de sujetos adultos con espondiloartritis axia...
    Medical condition: Espondiloartritis axial (AxSpA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051265 Spondyloarthropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) DE (Completed) BE (Completed) GB (Completed) DK (Prematurely Ended) NL (Completed) FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-002061-54 Sponsor Protocol Number: Re-IMPROVE Start Date*: 2016-10-13
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: "Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases. Evaluatio...
    Medical condition: Rheumatoid arthritis, seronegative spondylo arthritis, Crohn's Disease, Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    20.0 10017947 - Gastrointestinal disorders 10075634 Acute haemorrhagic ulcerative colitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011719-19 Sponsor Protocol Number: AS001 Start Date*: 2010-03-29
    Sponsor Name:SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
    Full Title: PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXIAL SPA)
    Medical condition: axial spondyloarthritis (axial SpA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002557 Ankylosing spondylitis and other inflammatory spondylopathies LLT
    12.1 10051265 Spondyloarthropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (Completed) HU (Completed) BE (Completed) IT (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-004226-15 Sponsor Protocol Number: Can-Art1 Start Date*: 2018-10-26
    Sponsor Name:King Christian 10th Hospital for Rheumatology
    Full Title: CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A rand...
    Medical condition: Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001970-41 Sponsor Protocol Number: 20170508 Start Date*: 2017-12-21
    Sponsor Name:MD, PhD Salome Kristensen
    Full Title: Dose reduction and discontinuation of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months randomised, open label, par...
    Medical condition: Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10040107 Seropositive rheumatoid arthritis LLT
    23.1 100000004859 10062719 Seronegative rheumatoid arthritis LLT
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    20.0 100000004859 10076297 Non-radiographic axial spondyloarthritis LLT
    21.1 100000004859 10041672 Spondylitis ankylosing LLT
    20.0 100000004859 10002557 Ankylosing spondylitis and other inflammatory spondylopathies LLT
    21.0 100000004859 10045966 Unspecified inflammatory spondylopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002631-33 Sponsor Protocol Number: CAIN457A2209 Start Date*: 2009-01-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis
    Medical condition: Ankylosing Spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:30:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA